Corporate & Investor Presentation

Track record of strong financial returns for shareholders Non-GAAP Revenue ($B) Operating Income ($M) Non-GAAP EPS $1.7 12% CAGR $3.0 LTM 4Q15 LTM 4Q20 16% CAGR $429 $891 LTM 4Q15 LTM 4Q20 13% CAGR $2.57 $4.76 LTM 4Q15 LTM 4Q20 Total Shareholder Return (NYSE shares as of 6/30/20): 1-yr 59% 3-yr 157% ☐ 5-yr 270% 37 2020 ResMed | Corporate & Investor Presentation - updated 05AUG20 ResMed

View entire presentation